Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
Department of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Paediatr Anaesth. 2021 Feb;31(2):205-212. doi: 10.1111/pan.14063. Epub 2021 Jan 4.
Anaphylactic reactions to antigens in the perioperative environment are uncommon, but they have a potential to lead to serious morbidity and/or mortality. The incidence of anaphylactic reactions is 1:37 000 pediatric anesthetics, and substantially less than the 1:10 000 to 1:20 000 incidence in the adult population. Neuromuscular blocking agents, latex, and antibiotics are the most frequently cited triggers. To date, there is no comprehensive report on perioperative anaphylactic reactions in children in the United States. Using the Wake-up Safe database, we examined the incidence and consequences of reported perioperative anaphylaxis events.
We reviewed the Wake-up Safe database from 2010 to 2017 and identified all reported instances of anaphylaxis. The triggering agent, timing, and location of the registered event, severity of patient harm, and preventability were identified. Narrative review of free-text comments entered by reporting centers was performed to determine presenting symptoms, and interventions required. Type of case was identified from procedure codes provided in mandatory fields.
Among 2 261 749 cases reported to the Wake-up Safe database during the study period, perioperative anaphylactic reactions occurred in 1:36 479 (0.003%). Antibiotics, neuromuscular blocking agents, and opioid analgesics were the main triggers. Forty-nine cases (79%) occurred in the operating room, and 13 cases (21%) occurred in off-site locations. Seven (11%) patients required cardiopulmonary resuscitation following the onset of symptoms. Thirty-five (57%) patients were treated with epinephrine or epinephrine plus other medications, whereas 5% were managed only with phenylephrine. Most cases (97%) required escalation of care after the event. Regarding case preventability, 91% of cases were marked as either "likely could not have been prevented" or "almost certainly could not have been prevented."
The estimated incidence of anaphylaxis and inciting agents among the pediatric population in this study were consistent with the most recent published studies outside of the United States; however, new findings included need for cardiopulmonary resuscitation in 11% of cases, and estimated fatality of 1.6%. The management of perioperative anaphylaxis could be improved for some cases as epinephrine was not administered, or its administration was delayed. Fewer than half of reported cases had additional investigation to formally identify the responsible agent.
围手术期环境中抗原的过敏反应并不常见,但它们有可能导致严重的发病率和/或死亡率。过敏反应的发生率为每 37000 例儿科麻醉,大大低于成人人群中每 10000 至 20000 例的发生率。神经肌肉阻滞剂、乳胶和抗生素是最常被提及的诱因。迄今为止,美国尚无关于儿童围手术期过敏反应的综合报告。我们使用“苏醒安全”数据库研究了报告的围手术期过敏反应事件的发生率和后果。
我们回顾了 2010 年至 2017 年期间的“苏醒安全”数据库,确定了所有报告的过敏反应事件。确定了触发剂、登记事件的时间和地点、患者伤害的严重程度以及可预防性。对报告中心输入的自由文本评论进行叙述性审查,以确定表现症状和所需干预措施。从强制性字段中提供的程序代码确定病例类型。
在研究期间向“苏醒安全”数据库报告的 2261749 例病例中,围手术期过敏反应发生率为 1:36479(0.003%)。抗生素、神经肌肉阻滞剂和阿片类镇痛药是主要的诱因。49 例(79%)发生在手术室,13 例(21%)发生在非现场地点。症状发作后,有 7 例(11%)患者需要心肺复苏。35 例(57%)患者接受肾上腺素或肾上腺素加其他药物治疗,而 5%仅用苯肾上腺素治疗。大多数病例(97%)在事件发生后需要升级治疗。关于病例的可预防性,91%的病例被标记为“可能无法预防”或“几乎肯定无法预防”。
本研究中小儿人群的过敏反应发生率和引发因素与美国以外最新发表的研究一致;然而,新的发现包括 11%的病例需要心肺复苏,估计死亡率为 1.6%。在某些情况下,肾上腺素未给予或给予延迟,围手术期过敏反应的管理可能需要改进。少于一半的报告病例有额外的调查来正式确定责任药物。